Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Lawrence Berkeley National Laboratory · scPharmaceuticals (United States) · +6 more institutions
Abstract
Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross-sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements.
We examined associations between mean cortical florbetapir uptake, mean (18) F-fluorodeoxyglucose-positron emission tomography (FDG-PET) within a set of predefined regions, and Alzhiemer's Disease Assessment Scale (ADAS-cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients). For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG-PET were associated with retrospective decline in longitudinal ADAS-cog measurements.
Citation impact
- FWCI
- 22.89
- Percentile
- 100%
- References
- 37
Authors
9- SLSusan LandauCorresponding
Lawrence Berkeley National Laboratory, scPharmaceuticals (United States), University of California, Berkeley
- MAMark A. Mintun
scPharmaceuticals (United States)
- ADAbhinay D. Joshi
scPharmaceuticals (United States)
- RARobert A. Koeppe
University of Michigan
- RCRonald C. Petersen
Mayo Clinic
Topics & keywords
- Cognitive decline
- Neuroimaging
- Positron emission tomography
- Cognition
- Internal medicine
- Subclinical infection
- Alzheimer's disease
- Cog
Funding
- FFFoundation for the National Institutes of HealthAwards: P30AG010129, K01 AG030514, Grant U01 AG024904, AG024904, U01 AG024904
- AAAlzheimer's AssociationAward: U01 AG024904
- DFDana FoundationAwards: K01 AG030514, U01 AG024904
- AAmgen
- BSBristol-Myers SquibbAwards: U01 AG024904, AG024904
- ELEli Lilly and CompanyAwards: U01 AG024904, AG024904
- PPfizerAwards: AG024904, U01 AG024904
- AAstraZeneca
- BBiogenAwards: U01 AG024904, AG024904
- FHF. Hoffmann-La RocheAwards: AG024904, U01 AG024904
- MMedpaceAward: U01 AG024904
- MSMeso Scale DiagnosticsAwards: U01 AG024904, AG024904
- SSynarcAwards: U01 AG024904, K01 AG030514
- ADAlzheimer's Disease Neuroimaging InitiativeAwards: AG024904, K01 AG030514, U01 AG024904
- ALAmorfix Life Sciences
- BBioClinicaAwards: U01 AG024904, AG024904
- NPNovartis Pharmaceuticals CorporationAwards: U01 AG024904, AG024904
- NCNorthern California Institute for Research and EducationAwards: U01 AG024904, K01 AG030514
- UOUniversity of Oxford
- BHBayer HealthCare
- EElanAward: U01 AG024904
- EEisaiAwards: U01 AG024904, AG024904
- APAstellas Pharma
- SServierAwards: AG024904, U01 AG024904
- NINational Institutes of HealthAwards: K01 AG030514, AG024904, U01 AG024904, P30AG010129, K01 AG030514, Grant U01 AG024904, AG030514, P30AG010129
- GGenentechAwards: AG024904, U01 AG024904
- UOUniversity of California, Los Angeles
- UOUniversity of California, San Diego
- ARAvid Radiopharmaceuticals
- CICanadian Institutes of Health ResearchAwards: U01 AG024904, K01 AG030514
- NINational Institute on AgingAwards: U01 AG024904, P30AG010129, AG024904, K01 AG030514
- NINational Institute of Biomedical Imaging and BioengineeringAwards: K01 AG030514, U01 AG024904, AG024904